INTRODUCTION
Mitochondrial diseases are a heterogeneous group of inborn errors with diverse patterns of clinical expression and in which an increasingly large variety of underlying biochemical defects is being recognized (Morgan-Hughes, 1986a, b) . One major subgroup is characterized by functional deficiencies of respiratory enzyme complexes (Morgan-Hughes et ai, 1987) . Clinically, patients may be difficult to categorize because of the range of age of onset, the great variability in the degree of functional disability and the absence of any characteristic patterns of organ involvement (DiMauro et ai, 1985; Petty et ai, 1986) . Defects of this type are typically associated with muscle weakness and fatiguability, a variable lactic acidaemia and 'ragged-red' muscle fibres (Olson et al, 1972) . Some patients have central nervous system (CNS) disease which may present with dementia, cerebellar ataxia, seizures, involuntary movements, deafness or acute stroke-like episodes. Other patients with identical biochemical defects in muscle may show no CNS involvement. The variable phenotype encountered in these disorders could be explained by the presence of tissue specific isoforms of the respiratory enzyme complexes under the control of nuclear genes (A. H. V. Schapira et al, unpublished results), or the presence of a heterogeneous population of normal and defective mitochondria in the ovum with random partitioning during embryogenesis (Egger and Wilson, 1983) .
For obvious reasons these biochemical defects have been identified in easily accessible tissues suitable for biopsy and the in vitro isolation of functionally intact mitochondrial samples. Positron emission tomography (PET) provides a quantitative tracer method to measure tissue energy metabolism in inaccessible tissues in vivo . Techniques have been well described, validated and applied to man for measurement of the regional metabolism of oxygen (Frackowiak et al, 1980; Baron et al, 1981; Lammertsma et al, 1981 Lammertsma et al, , 1982 Rhodes et al, 1981; Lammertsma and Jones, 1983a) and glucose in the brain (Phelps et al, 1919b; Reivich et al, 1979) . The measurement of glucose metabolism depends on the steady-state measurement of the flux of glucose through the first (hexokinase) step of the glycolytic pathway. On the other hand, the technique for making measurements of oxygen consumption depends on the generation of metabolic water in respiring tissue by the acceptance of reducing equivalents transferred down the respiratory chain (Jones et al, 1976) . The combination of these two measurements provides a method for the analysis of cellular bioenergetics in vivo (Baron et al, 1984) . The normal molar stoichiometry between oxygen and glucose utilization in the human brain is 5.6 (Lassen, 1959) . The remaining 0.4 moles are accounted for by other routes of glucose metabolism, for example to lactate or other intermediate metabolites.
Marked deviations from this relationship would be expected when oxidative metabolism is impaired. In such cases less oxygen than normal will be consumed per mole of glucose metabolized.
The aim of the study was to determine whether there were differences in oxidative metabolism in the brains of patients with identified biochemical defects in muscle mitochondria who differed in their clinical expressions.
MATERIAL AND METHODS

Clinical details
Seven normal volunteers, 5 males and 2 females aged between 23 and 53 yrs (34+ 10.5, mean + SD) were studied. They had no history of previous neurological or psychiatric illness, or general medical disease. All were either graduates in gainful employment or full-time students.
Seven patients with mitochondrial respiratory chain deficiencies and 1 patient with H + -ATPase deficiency were studied: 4 had evidence of major CNS disease and 4 had myopathy alone. The 4 with CNS disease were aged 23 to 64 yrs (48 ± 18, mean ± SD); there were 3 males and 1 female. The 4 with no signs of CNS disease were aged 21 to 56 yrs (38 ±17, mean ± SD); there were 3 females and 1 male. The locus of the biochemical defect in each case is shown in Table 1 . Biochemical studies were carried out on freshly isolated skeletal muscle mitochondria according to previously described methods (MorganHughes et al., 1982) .
Case histories
No CNS disease Case I (No. 927) . A 21-yr-old woman with weakness and exercise intolerance since early childhood. Her birth and early development were normal. She walked at 1 yr but tired easily and was less active than her peers. She was unable to run or play games at school and at the age of 11 yrs she developed unexplained congestive heart failure which resolved spontaneously after several months. The weakness and fatigue became worse in her late teens and she developed exercise-induced myalgia in her calves. Examination revealed generalized weakness with fatiguability of the sternomastoid, limb and trunk muscles with normal reflexes and flexor plantar responses. There was no clinical or laboratory evidence of CNS, retinal or cardiac involvement. The serum CK was 199 IU/1 (normal < 80 IU/1), an ECG was normal and an echocardiogram revealed a bicuspid aortic valve. A CT brain scan was normal. EMG studies showed myopathic potentials with normal motor and sensory conduction. A standard 10 min exercise test on a bicycle ergometer showed a rise in venous blood lactate from 1.3 to 5.7 mmol/1 after 10 min which was still elevated at 3.8 mmol/1 after 30 min. A muscle biopsy showed 34% of'ragged-red' fibres containing elongated mitochondria with transverse cristae. Her sister died aged 23 yrs of cardiorespiratory failure and severe lactic acidosis (Morgan-Hughes et al., 1985, Case 1; Wiles et al., 1986) .
Case 2 (No. 878) . A 56-yr-old woman with a 40 yr history of muscle fatiguability and weakness, and myalgia. For several years she had noticed difficulty in climbing stairs and getting out of a low chair. On examination, she had mild diffuse weakness of the limbs, more marked proximally. The reflexes and plantar responses were normal. The serum CK, ECG and CT brain scan were normal. A muscle biopsy showed occasional 'ragged-red' fibres and increased neutral lipid droplets in type 1 and 2a fibres. Total muscle carnitine measured 1.14 /jmol/g wet weight (control mean + SD = 2.0±0.7, n = 28). Her daughter was similarly affected (Clark et al., 1984) . Case 3 (No. 939) . A 49-yr-old man with a 2 yr history of progressive weakness, severe exercise intolerance and proximal myalgia. When first seen he could only walk about 100 yards on the flat before having to rest and could climb only one flight of stairs. On examination he had weakness with fatiguability affecting the sternomastoid, limb and trunk muscles and was unable to rise from a squatting position without help. The reflexes were sluggish but the plantar responses were flexor. An ECG and serum CK were normal. During a standard exercise test the venous blood lactate rose from 0.3 mmol/1 to 3.0 mmol/1 after 15 min. The EMG was myopathic; nerve conduction velocities were normal. Muscle biopsy showed the changes of a lipid storage myopathy with numerous 'ragged-red' fibres. Total muscle carnitine was low at 0.22 /jmol/g wet weight (controls 2.0 + 0.7) but plasma carnitine was normal (Morgan-Hughes el al., 1985) . Case 4 (No. 933) . A 27-yr-old female with weakness and exercise fatiguability since childhood and ptosis since her late teens. She walked at 18 months and fell frequently during childhood. She was unable to run or play games at school and had intermittent diplopia when tired. Menarche was delayed until she was 20 yrs of age. On examination she had bilateral ptosis, marked limitation of extraocular movements, with facial, sternomastoid and diffuse limb and trunk weakness. The reflexes and plantar responses were normal and sensation was intact. The serum CK, CSF, ECG and a CT brain scan were normal. EMG studies showed myopathic potentials; nerve conduction velocities were normal. Venous lactate levels rose from 0.9 to 4.5 mmol/1 during a standard exercise test. Muscle biopsy showed 20% 'ragged-red' fibres.
With CNS disease
Case 5 (No. 748) . A 46-yr-old man with a 6 yr history of progressive deafness, forgetfulness, personality change and ataxia of gait. On examination he was euphoric and demented (verbal IQ 67; performance IQ 80), with bilateral sensorineural deafness, scanning cerebellar dysarthria, a broadbased ataxic gait and choreic limb movements. Muscle bulk and power were normal. Sensation and reflexes were normal but the plantar responses were extensor. EMG studies showed evidence of denervation in the distal limb muscles and absent sensory nerve action potentials but normal motor conduction. A CT brain scan showed cerebral and cerebellar atrophy with areas of low attenuation in white matter. The serum CK, CSF, ECG and EEG were normal. Venous blood lactate levels rose to 1.9 mmol/1 after 10 min exercise. A muscle biopsy showed minor neurogenic changes with 30% 'ragged-red' fibres (Morgan-Hughes el al., 1985, Case 3) . Case 6 (No. 911) . A 23-yr-old male was normal until aged 5 yrs when he developed intermittent headaches, recurrent episodes of unexplained vomiting, easy fatiguability, exertional dyspnoea and intellectual deterioration. These symptoms progressed until the age of 9 when he had a generalized seizure. Investigations at this time showed calcification of the basal ganglia on CT, raised CSF protein, sensorineural hearing loss and short stature. Muscle biopsy showed a lipid storage myopathy with 'ragged-red' fibres and a muscle carnitine concentration of 2.6 ^mol/g dry weight (Smyth el al., 1975) . On treatment with oral carnitine the vomiting stopped and there was gradual improvement in muscle strength, but he went on to develop progressive intellectual deterioration, cerebellar ataxia and a peripheral sensory neuropathy. On examination he was demented (verbal IQ 71; performance IQ 40) and dysarthric, with a broad-based ataxic gait. He had a pigmentary retinopathy of the 'salt-andpepper' type, mild facial weakness and diffuse weakness with fatiguability in the limbs with hyporeflexia and extensor plantar responses. Vibration and position sense was impaired in the toes and fingers. The serum CK and ECG were normal. EMG studies showed myopathic potentials with an axonal sensorimotor neuropathy. A CT brain scan showed generalized atrophy with calcification of the basal ganglia. An EEG showed paroxysmal slow wave activity. Repeat muscle biopsy at 17 yrs of age showed disappearance of lipid storage and 20% 'ragged-red' fibres. Total muscle carnitine concentration was also normal (Clark el al, 1984, Case 1).
Case 7 (No. 1206).
A 58-yr-old man presented with an 8 yr history of progressive deafness and ataxia of gait. For 3 yrs he had had difficulty in climbing stairs and for a year had noticed poor memory. Since his twenties he had frequently complained of lethargy and fatigue and when aged 31 had developed insulin-dependent diabetes. On examination he was mildly demented (verbal IQ 85; performance IQ 84) with an ataxic gait, cerebellar dysarthria and severe sensorineural deafness. There was mild diffuse weakness with fatiguability in the limbs with reduced muscle bulk, absent tendon reflexes and flexor plantar responses. Pain and light touch were diminished in a glove and stocking distribution. The serum CK was 167 IU/1 (normal < 80 IU/1), random venous blood lactate levels were 3.0 and 2.6 mmol/1 (normal up to 1.8 mmol/1) and the CSF protein was 0.6 g/1. An EEG showed left ventricular hypertrophy and inverted left ventricular T waves. A CT brain scan showed cerebral and cerebellar atrophy. EMG studies showed a motor and sensory axonal neuropathy. Muscle biopsy showed mild denervation and about 40% 'ragged-red' fibres.
Case 8 (No. 846) . A 64-yr-old female with a 3 yr history of progressive dysarthria, ataxia of gait and impaired memory. On examination, she was small (140 cm) and mildly demented (verbal IQ 91; performance IQ 72). There was marked limb and gait ataxia and mild weakness with fatiguability of proximal limb muscles. The tendon reflexes were brisk and the plantar responses extensor, but sensation was normal. The serum CK was normal. EMG studies showed myopathic potentials. Nerve conduction velocities were normal. A CT brain scan showed cerebral, brainstem and cerebellar atrophy with areas of low attenuation in white matter. Muscle biopsy showed mild myopathic changes and 20% 'ragged-red' fibres.
Positron tomography
Patients and normal volunteers were scanned with oxygen-15 labelled tracers (' 5 O 2 and C 15 O 2 ) and with fluorine-18 labelled 2-deoxy-D-glucose ( 18 FDG). Selected studies with carbon-11 labelled carbon monoxide ("CO) were also performed (Phelps et al., 1979a) .
All measurements were made with the ECAT II tomograph (CTI Inc., Knoxville, Tennessee) with a transaxial resolution at full width half maximum (FWHM) of 1.6 cm in x and y axes and 1.7 cm in the z axis. Patients and subjects were scanned recumbent with minor head restraint and constant supervision of head immobility. The eyes were closed and ears unplugged in conditions of minimum ambient noise and tactile stimulation. A 21 gauge, 3 cm Teflon catheter was placed in a radial artery before positioning the subject in the tomograph. All subsequent blood samples were taken without disturbing the subject. An intravenous catheter was placed in the contralateral arm for the administration of' 8 FDG. Gaseous tracers were administered through a loose fitting plastic face mask. Scans were performed through one transaxial plane at the level of the insula and basal ganglia (OM + 4-OM + 5 cm) only. Positioning was determined from a short emission scan during the initial phase of inhalation of 15 O-labelled gas.
Oxygen consumption
The steady state inhalation method was used for the measurement of oxygen metabolism (CMR O J and blood flow (CBF) (Frackowiak et al, 1980; . Trace quantities of C"O 2 were continuously inhaled by the patient. Within 10 min a dynamic steady-state was reached during which radioactivity recorded from the head remained constant with time. The plane of interest was scanned for 5 min allowing the accumulation of 1.0-1.5 x I0 6 counts. During scanning, 3 arterial samples were drawn for measurement of plasma and whole blood activity. The inhalation was stopped and after waiting a further 10 min for the activity to decay away (t^' 5 O = 2.1 min), an inhalation of 15 O 2 was commenced and a second scan recorded at a similar dynamic equilibrium. The 15 O 2 scan was followed by a transmission scan, using a 68 Ge/ 68 Ga external ring source, for the purposes of correcting all the emission scans accurately for attenuation.
Glucose consumption
Cerebral glucose consumption (CMR G ,J was measured with a kinetic modification of the Sokoloff analogue tracer technique (Sokoloff et al., 1977) using 18 FDG (Lammertsma et al., 1987) . Following decay of the ' 5 O activity, between 3 and 7 mCi of' 8 FDG in 10 ml of saline were given intravenously by Harvard pump over 2 min. Simultaneously, arterial blood sampling for measurement of radioactivity was started and performed every 20 s for 3 min, 30 s for a further 2 min, every 1 min until 10 min, every 3 min until 20 min and then at 5 min intervals until the end of scanning at 50-60 min. Scanning was commenced at the beginning of 18 FDG infusion with five consecutive 1 min scans followed by six 5 min scans and ending with a 5-10 min scan starting 45 min after injection of tracer. The last scan generated 0.3-0.8 x 10 6 counts in the plane of interest. Four plasma glucose measurements were also made.
Blood volume and correction of CMR O2
Finally, in 2 normal subjects and 6 patients a 2 min inhalation of "CO was followed by a 5 min equilibration period and a final scan to determine the distribution of the blood volume tracer (Phelps et ai, 1979a) . As the half life of 18 F is 110 min, residual background activity from the 18 FDG procedure contaminated the '' CO signal. This contaminating activity was therefore removed from the ' 'CO data by decay correcting the final I8 FDG scan to the time of the "CO scan and subtracting. This, and all the corrections involving tracer distributions, was made possible because a number of techniques were used to ensure that the subject's head remained immobile throughout the study and hence that the activity distributions were spatially congruent. Three blood samples were obtained to calculate the cerebral blood volume (CBV) from the corrected "CO scan. A value of 0.85 was taken from the literature for the peripheral cerebral to venous haematocrit ratio necessary for calculation of CBV (Larsen and Lassen, 1964) . The CBV is required to correct the ' 5 O 2 data for intravascular activity so that fractional oxygen extraction and hence CMR O; can be accurately calculated . It proved impossible to perform "CO scans on all subjects and patients. In those in whom it was not done, a value for CBV was derived from the corresponding value for CBF. It is known from previous studies that there is normally a close correlation between CBF and CBV (Grubb et ai, 1977) . In each of the three groups the CBF/CBV ratio was calculated from the available, measured, complete data sets. A CBV was then calculated for those in whom it had not been measured, from the measured CBF and the mean group CBF/CBV ratio. The correction for intravascular 15 O 2 is important as its lack will cause an overestimation in OER and hence CMR Oi by approximately 20%. However, correction with an estimated CBV, even if in error by as much as 15%, will result in at most an error of 1-2% in CMR O2 Lammertsma el ai, 1983) . This approximation is therefore justified and was applied to 1 patient in each of the 2 patient groups and to 5 of the 7 normal subjects.
Blood volume and calculation of CMR a]u
The CBV data are also necessary for subtraction of vascular activity from the 18 FDG scans, particularly early on when the tissue signal is contaminated significantly by intravascular tracer. This subtraction allows the accurate construction of an extravascular tissue time-activity curve from the sequentially collected scan data for any region of interest in the scanned plane. The tissue uptake of tracer in response to the vascular tracer input function, which is measured by blood sampling, can therefore be described. A kinetic, least squares, computerized curve-fitting procedure permitted the unique solution of the data in terms of 4 kinetic rate constants. These describe the transport of the tracer from blood into tissue and in the reverse direction (kf and k|), phosphorylation of free tracer in the tissue by hexokinase and any hydrolysis of the accumulated product that may occur (kf and kj). The curve analysis was rendered more accurate by fitting for the product [kf kj/(kf+ kj)] directly. This expression when multiplied by the plasma glucose concentration and divided by a 'lumped constant' (LC), which is a factor that relates the behaviour of the analogue tracer' 8 FDG to the natural substrate glucose, gives the CMR Glll , i.e.
CMR G|U = {[glucose] p /LC} x {k* k?/(kf + k?)} where [glucose] p is the plasma glucose concentration. The LC used in these studies was derived empirically from knowledge of the molar relationship between oxygen and glucose consumption in the brains of normal young men, which has been shown to be 5.6 (Lassen, 1959) . LC was therefore calculated using the CMR Oj data from the normal subjects in this study. The value of this empirical 'lumped constant' (LC = 0.75) is higher than that conventionally used (0.42, Phelps et ai, 1979b) or that measured using arteriovenous difference techniques in 3 volunteers by Reivich et ai, 1979 (0.54) . The reasons and justification for this approach will be found in the Discussion. The total time taken to collect a set of measurements with the PET scanner was under 2 h without a CBV scan and under 2.25 h if one was included. The scans were analysed using the cortical plot technique previously described (Wise et ai, 1983) . This centres on 2 hemisphere middle cerebral artery regions of interest of 1.5 cm width. They encompass the area of maximal peripheral activity in the scan corresponding to the cortical ribbon, but which also include some underlying white matter. The results from the 2 hemisphere plots were averaged for each subject as no significant right/left asymmetries were discovered.
The protocols were approved by the research ethics committee of the Hammersmith and National Hospitals and by the Administration of Radioactive Substances Advisory Committee of the DHSS.
RESULTS
Blood biochemistry is tabulated for normal subjects and patients in Table 2 .
Normal subjects
The results in normal subjects are presented in Table 3 . The mean CMR O2 for the group of 7 normal subjects was found to be 153 + 14.5 /imol/dl/min (3.4 + 0.3 ml/dl/min), the CMR Glu was 27.4 + 2.4 /imol/dl/min (4.9 ±0.4 mg/dl/min) and the molar ratio (M R) between the two was 5.6 + 0.6. As described above, the LC used in calculations of CMR Glu was derived empirically from an assumed normal MR of 5.6, the measured CMR O2 , the kinetic rate constants obtained from 18 FDG scanning and the plasma glucose concentrations in the 2 subjects in whom CBV was also measured. This value when applied to the whole group of 7 normal subjects resulted in a mean MR of 5.6, indicating the consistency of the approach. The group CBF was 43.9 + 7.4 ml/dl/min which is slightly lower than that found in smaller and more homogeneous grey-matter regions in normal volunteers. This indicates that the method of cortical strip analysis results in some contamination of cortical grey matter by underlying white matter, an inevitable consequence of the relatively coarse resolution of the ECAT II PET camera. The fractional oxygen extraction (OER) was 0.42 + 0.06 and the fractional glucose extraction (GER) 0.12 + 0.02.
Patients without cerebral symptoms
The results in patients with respiratory chain defects without cerebral symptoms are presented in Table 4 . The mean CMR O2 and CMR G)u were 152 + 27/zmol/dl/min and 23.5 ± 1.4 /imol/dl/min (3.4 + 0.6 ml/dl/min and 4.2 + 0.3 mg/dl/min) respectively, giving an MR of 6.4+1.1. The mean CBF was 39.5 + 3.3 ml/dl/min, the OER 0.47±0.05 and the GER 0.11+0.01.
Patients with cerebral symptoms
The results in patients with mitochondrial myopathy and CNS disease are given in Table 5 . Mean CMR O; and CMR Glu were 77.1 +15.2 /zmol/ml/min and 20.3 + 1.9 //mol/ml/min (1.7 ±0.3 ml/dl/min and 3.7 ±0.3 mg/dl/min), resulting in a very significantly decreased MR of 3.8 + 0.8 (P < 0.005). The mean CBF was 30.6 + 6.9 ml/dl/min, the OER 0.36 + 0.1 and the GER 0.10 + 0.03. The large spread in the OER value was due to a low value in 2 of the patients and a normal value in the 2 others.
FDG kinetic constants
The kinetic constants for the 3 groups are presented in Table 6 . The ratio [k* k*/(k* + k1f)] is used to calculate CMR G!u . The curve-fitting procedure used to calculate this function permits direct estimation of the standard error (SE) for each fit, which gives an estimate of the SE of the calculated value of CMR G , U . The SE was 4.4 ±2.2% in the normal group, 6.7 + 2.8% in those without cerebral symptoms and 8.4 + 2.8% in those with cerebral symptoms giving a mean SE of 6.2 + 2.9%. The rate of apparent hydrolysis (k*) was very similar in all 3 groups and approximately 11% that of phosphorylation (k*). Curve fitting with only 3 constants, ignoring k*, gave less good fits for the rate constants and the function [k*k*/(k* + k*]. 
Statistical analysis
An analysis of variance (one way ANOVA) was performed to assess the significance of differences between groups ( Table 7) . The significance of differences in MR between patients and normals was then tested with a two-tailed Student's t test.
DISCUSSION
These results provide strong direct evidence that in patients with mitochondrial encephalopathy the functional defect identified in freshly isolated skeletal muscle is also expressed in cerebral tissue. The marked decrease of over a third in the molar ratio indicates that in these patients approximately 4 molecules of oxygen, rather than the expected 6, are consumed per molecule of glucose. This implies the aerobic glycolysis of up to a third of the glucose metabolized in the brain, presumably to lactate and other intermediate metabolites (e.g., pentose phosphate shunt intermediates and 2-carbon metabolic products of the Krebs cycle). This deranged metabolism of glucose is occurring in the context of normal tissue oxygenation as demonstrated by the normal, and sometimes subnormal, fractional extraction of oxygen (OER). If oxidative phosphorylation is impaired due to a primary defect of mitochondrial function, excess ADP and/or NADH + will stimulate glycolysis via phosphofructokinase. The results support this hypothesis. The rate of oxygen metabolism was profoundly depressed in the patients with CNS disease and correlated with the rank order of dementia (estimated with the WAIS) in the 4 patients. The depression of CMR O2 of 50% contrasts with the much lower reduction in the CMR Glu of only 26% and with the normal CMR O2 in the patients without CNS disease.
A second observation in the group with CNS disease is the presence of a low OER in the 2 patients with the severest cerebral disease. This implies a disturbance in the normal coupling between perfusion and energy metabolism in these patients. The mechanism for this is unclear at present. A possibility is that local cerebral lactate production may be high with perhaps an associated tendency to cerebral lactic acidosis. However, Berkovic et al. (1987) have recently described, in an abstract, studies in 3 patients with myoclonic epilepsy and 'ragged-red' fibres and noted no change in cerebral pH (measured with PET) and a normal intracellular pH measured in 1 patient with MRI.
The molar ratio in patients with respiratory chain defects but without CNS disease was 14% higher than in normal subjects, although the difference was not statistically significant. It is known that glucose is the preferred and normally the virtually exclusive substrate of the brain for energy production. However, in ketotic states ketone bodies can function as alternative substrates because uptake is passive and concentration dependent. Patients with respiratory chain defects frequently develop ketonaemia (see clinical descriptions above). It is therefore possible that in some patients without CNS disease and with apparently normal cerebral energy metabolism, the slight excess of oxygen molecules consumed for the amount of glucose metabolized (i.e., > 6) is explained by oxidation of ketone bodies.
There is little or no information about the stoichiometry between glucose and oxygen metabolism measured in the same individuals with other dementing conditions. Alzheimer's disease is known to be associated with a reduction of 20-40% in CMR O2 that is correlated with the severity of the dementia . Similar findings have been reported from a number of laboratories for glucose metabolism (for review, see Frackowiak, 1987) . The literature does not therefore support the suggestion that dementia per se is associated with a differential impairment of oxygen and glucose metabolism. The pattern observed in this study is probably specific to respiratory chain defects. One study (J. Hatazawa, personal communication), measuring CMR O; and CMR Glu in the same patients suffering from Alzheimer's disease, showed apparently little change in the molar ratio with, if anything, a tendency towards an increase.
No focal abnormalities were observed in the cortical grey matter of subjects which could be related to different focal signs or symptoms. However, the data were collected on a tomograph with single-slice scanning capacity and had to be restricted for practical reasons to measurements from 1 plane only on this account. The possibility that focal changes might be observed needs to await further studies using multislice machines. A number of patients develop CNS symptoms and signs a considerable time after muscle disease first declares itself. The question arises whether such patients show disturbances of cerebral energy metabolism before the onset of overt CNS disease. The answer to this question also awaits further studies.
The results of the study are clear cut, but certain methodological features require discussion. The use of an empirically derived 'lumped constant' (LC) might be criticized. However, the LC used conventionally (0.42) was likewise defined empirically by reference to a normal CMR Glu for human brain measured by arteriovenous sampling techniques (Phelps et al, 19796) . More recently, an LC of 0.54 has been measured in 3 normal subjects by a direct arteriovenous sampling method (Reivich et al, 1985) . An LC of 0.75 was used in this study. This is a combination of the true LC (which cannot be measured in each study) and an empirical correction factor and allows for a meaningful comparison of the CMR G | U and CMR O2 results. The empirical nature of LC is justified on the grounds that it uses direct whole brain measurements of CMR G)u obtained with arteriovenous difference methods for calibration, a procedure analogous to that of Phelps et al. (1979b) . The major reason why an LC higher than the true LC is necessary is that the mean cortical CMR O2 measured by the steady-state oxygen inhalation technique may be underestimated by as much as 20% because of the admixture of grey and white matter in the region of interest (Lammertsma et al, 1981) . As a result, the LC will be 20% higher if it is defined in terms of CMR Oj values measured by the steady-state method. A second consideration is the effect that the measurement of CBV to correct for intravascular activity during 18 FDG scanning has on the LC. The measurement of CBV depends on knowledge of the peripheral venous to cerebral vessel haematocrit ratio. This has been conventionally taken as 0.85, the average of a number of studies in various animal species (Larsen and Lassen, 1964) . Recently we have measured cerebral haematocrit with PET and found that the value of the haematocrit ratio in man is much closer to 0.7 . The use of this ratio, instead of the conventional 0.85 for the calculation of CBV, results in an overestimation of CMR G)u by up to a maximum of 10%. This serves to increase LC in relation to LC by a further 10%. Thus the empirically derived LC of 0.75 we have used compares favourably with the measured 0.54 adjusted upwards by 30% (0.70) to compensate for the above factors. Finally, there may be a small effect on the LC by virtue of the fact that chemical preparations of 18 FDG have until very recently been contaminated by up to 20% 18 F deoxymannose. In conclusion, as the aim of this study was to investigate the relationship between oxygen and glucose metabolism, the use of a pragmatic LC, defined empirically as described and applied to all the data seems adequately justified. It is notable that others who have attempted stoichiometric measurements in the past have consistently underestimated the molar ratio due to a combination of factors dependent on the precise methods of measurement (Baron et al., 1984) .
We have measured CMR Glu kinetically. The rate constants are somewhat different to standard published values in normals {see Mazziotta and Phelps, 1986) . There are several reasons for this. (1) The blood data in this study were obtained by arterial sampling. Others have frequently obtained these data by sampling from a heated, 'arterialized' hand vein. The former technique is more accurate (Budinger et al., 1985) , although many of the published rate constants have been measured using venous sampling (Phelps et al, 1979ft; Reivich et al, 1979) . (2) The correction for attenuation in this study has been measured rather than geometrically manipulated, which is also more accurate; this should not, however, affect the rate constant values significantly. (3) A correction for intravascular tracer has been applied by measurement of CBV, which has not been uniformly practised in the past. This is particularly important in kinetic analysis of the earliest phases after tracer injection when the intravascular activity dominates tissue activity. The CBV correction by measurement therefore makes the estimation of k? more accurate. (4) The introduction of tracer by pulse injection may result in inadequate sampling of blood radioactivity during the initial short-lived peak of blood activity. We have therefore infused the tracer slowly over 2 min, smoothing out the initial phase of the input function, and allowing its more accurate definition by 20 s blood sampling over the first 3 min. (5) The study time of up to 60 min makes the accurate estimation of k* difficult as hydrolysis is a slow and largely insignificant process at this time (Sokoloff et ai, 1977) . This results in a tendency to overestimate kj and hence the reverse constant kf, which enters into the calculation of CMR G | U . The equation for the calculation of CMR Glu indicates that the rate constants are themselves interrelated and interdependent so that errors in the estimation of individual constants are substantially minimized in the final calculation of CMR Glu (Sokoloff et ai, 1977) . This is clear on inspection of the standard deviations of the rate constants and a comparison with the much smaller standard error of 6.2% for the derived function k*kf/(kf + kjjr). The kinetic constants in Table 6 are sufficiently similar between the 3 groups that the alteration in MR would be very unlikely to result from major changes in the true LC which might be brought about by altered handling of 18 FDG and glucose at the blood-brain barrier or the hexokinase step as a result of the disease process itself.
The heterogeneity of clinical features in patients with similar underlying biochemical defects is puzzling. The major changes in energy metabolism we have demonstrated would support the hypothesis that the distribution of the biochemical abnormality is not uniform in all the tissues of the body. Thus patients with CNS disease have evidence of disturbed cerebral energy metabolism, whereas those without CNS signs or symptoms do not. This might be explained by dysfunction of tissue specific isoforms of the enzymes or alternatively by a difference in dose and segregation of defective mitochondria during early embryogenesis, if the mode of transmission of this group of disorders is indeed cytoplasmic and maternal (mitochondrial). It may be possible to define the heterogeneous distribution of biochemical dysfunction in the various body tissues in the future more directly by whole body scanning of affected young children. Alternatively, PET could be used to measure tissue pH using tracers such as n CO 2 or "C-DMO (Syrota et ai, 1983; Brooks et ai, 1984; Buxton et ai, 1984 Buxton et ai, , 1986 ; and see Berkovic et ai, 1987) .
